Vivimed Labs Limited (NSE:VIVIMEDLAB)
India · Delayed Price · Currency is INR 5.50
+0.10 (1.85%)
Nov 11, 2026, 2:58 PM IST
Vivimed Labs Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 456 | 438 | 410 | 410 | 547 | 1,202 | |
Market Cap Growth | 11.11% | 6.67% | 0% | -25.00% | -54.48% | -9.94% |
Enterprise Value | 4,416 | 4,268 | 4,182 | 3,585 | 4,190 | 4,763 |
Last Close Price | 5.40 | 5.28 | 4.95 | 4.95 | 6.60 | 14.50 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Forward PE | - | 3.14 | 3.14 | 3.14 | 3.14 | 3.14 |
PS Ratio | 0.59 | 0.57 | 0.34 | 0.26 | 0.29 | 0.50 |
PB Ratio | - | -0.21 | -1.17 | -7.52 | 1.39 | 0.33 |
P/TBV Ratio | - | - | - | - | - | 0.58 |
P/FCF Ratio | 6.63 | 6.48 | - | - | 1.80 | 10.80 |
P/OCF Ratio | 5.81 | 5.68 | - | - | 1.55 | 4.37 |
PEG Ratio | - | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 5.78 | 5.59 | 3.47 | 2.25 | 2.23 | 2.00 |
EV/FCF Ratio | 65.24 | 63.18 | - | - | 13.80 | 42.79 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | -1.89 | -1.89 | -10.70 | -69.36 | 9.67 | 0.99 |
Debt / FCF Ratio | 58.81 | 58.81 | - | - | 12.55 | 32.24 |
Net Debt / Equity Ratio | -1.88 | -1.88 | -10.68 | -68.99 | 9.57 | 0.97 |
Net Debt / EBITDA Ratio | -2.71 | -2.71 | -43.54 | -17.23 | -2.03 | -51.79 |
Net Debt / FCF Ratio | 58.61 | 58.61 | -59.79 | -14.47 | 12.43 | 31.60 |
Asset Turnover | 0.09 | 0.09 | 0.13 | 0.16 | 0.17 | 0.19 |
Inventory Turnover | 2.06 | 2.06 | 1.00 | 1.00 | 1.71 | 0.63 |
Quick Ratio | 0.10 | 0.10 | 0.18 | 0.21 | 0.18 | 0.25 |
Current Ratio | 0.38 | 0.38 | 0.80 | 0.84 | 0.80 | 1.36 |
Return on Equity (ROE) | - | - | - | -267.64% | -162.76% | -17.00% |
Return on Assets (ROA) | -12.85% | -12.85% | -1.93% | -2.69% | -11.34% | -1.23% |
Return on Invested Capital (ROIC) | -56.38% | -42.09% | -5.48% | -8.73% | -36.21% | -3.42% |
Return on Capital Employed (ROCE) | -56.40% | -56.40% | -5.60% | -7.70% | -35.90% | -2.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -384.55% | -403.10% | -77.87% | -110.73% | -600.36% | -56.27% |
FCF Yield | 15.09% | 15.43% | -15.31% | -63.42% | 55.47% | 9.26% |
Buyback Yield / Dilution | -0.63% | -0.63% | - | - | - | - |
Total Shareholder Return | -0.63% | -0.63% | - | - | - | - |